Allarity Therapeutics, Inc. (NASDAQ:ALLR – Get Rating) was the target of a large increase in short interest in December. As of December 15th, there was short interest totalling 112,200 shares, an increase of 2,852.6% from the November 30th total of 3,800 shares. Based on an average daily volume of 556,700 shares, the short-interest ratio is presently 0.2 days. Approximately 1.3% of the company's stock are sold short.
Allarity Therapeutics Price Performance
Shares of Allarity Therapeutics stock traded down $0.01 during trading on Wednesday, hitting $0.22. 7,272 shares of the company's stock traded hands, compared to its average volume of 1,628,587. Allarity Therapeutics has a 1 year low of $0.22 and a 1 year high of $12.86. The business has a 50-day simple moving average of $0.47 and a 200-day simple moving average of $0.97. The company has a current ratio of 0.47, a quick ratio of 0.47 and a debt-to-equity ratio of 0.73.
Get
Allarity Therapeutics alerts:
Allarity Therapeutics (NASDAQ:ALLR – Get Rating) last released its quarterly earnings data on Friday, October 7th. The company reported ($0.72) earnings per share for the quarter. As a group, sell-side analysts anticipate that Allarity Therapeutics will post -1.62 earnings per share for the current year.
Institutional Trading of Allarity Therapeutics
An institutional investor recently bought a new position in Allarity Therapeutics stock. Renaissance Technologies LLC purchased a new stake in shares of Allarity Therapeutics, Inc. (NASDAQ:ALLR – Get Rating) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 114,227 shares of the company's stock, valued at approximately $233,000. Institutional investors and hedge funds own 1.61% of the company's stock.
About Allarity Therapeutics
(Get Rating)
Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.
Read More
- Get a free copy of the StockNews.com research report on Allarity Therapeutics (ALLR)
- The Top Three Stocks Analysts Say To Buy
- Can Dick's Sporting Goods Stock Score Another Win In Q4?
- Why Did Immutep Ltd Stock Soar Recently?
- Yum! Brands Looks Tasty in 2023
- 3 Industrial Stocks to Help Build Your 2023 Watchlist
Receive News & Ratings for Allarity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allarity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
